Browsing by Author "Martínez-García, Maria"

Sort by: Order: Results:

  • Esteve-Codina, Anna; Arpí Llucià, Oriol; Martínez-García, Maria; Pineda, Estela; Mallo, Mar; Gut, Marta; Carrato, Cristina; Rovira Guerín, Ana; Lopez, Raquel; Tortosa, Avelina; Dabad, Marc; del Barco, Sonia; Heath, Simon; Bagué, Silvia; Ribalta, Teresa; Alameda Quitllet, Francisco; de la Iglesia, Nuria; Balaña, Carmen; GLIOCAT Group (Public Library of Science (PLoS), 2017)
    The molecular classification of glioblastoma (GBM) based on gene expression might better explain outcome and response to treatment than clinical factors. Whole transcriptome sequencing using next-generation sequencing ...
  • Cejalvo, Juan M.; Jacob, Wolfgang; Fleitas Kanonnikoff, Tania; Felip, Enriqueta; Navarro Mendivil, Alejandro; Martínez-García, Maria; Taus García, Álvaro; Leighl, Natasha; Lassen, Ulrik; Mau-Soerensen, Morten; Adessi, Celine; Michielin, Francesca; James, Ian; Ceppi, Maurizio; Hasmann, Max; Weisser, Martin; Cervantes, Andrés (BMJ Publishing Group, 2019)
    PURPOSE:This study investigated the safety and clinical activity of lumretuzumab, a humanised antihuman epidermal growth factor receptor 3 (HER3) monoclonal antibody, in combination with carboplatin and paclitaxel in ...
  • Gómez-Roca, Carlos; Taus García, Álvaro; Martínez-García, Maria; Marabelle, Aurelien (BMJ Publishing Group, 2022)
    Background: this phase 1b study (NCT02323191) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of colony-stimulating factor-1 receptor-blocking monoclonal antibody (mAb) emactuzumab in ...
  • Sabbaghi Mehrjardi, Mohammad Ali; Gil Gómez, Gabriel; Guardia Laguarta, Cristina; Servitja Tormo, Sonia; Arpí Llucià, Oriol; Menendez Romero, Silvia; Arumí, Montserrat; Serrano, Laia; Salido Galeote, Marta; Muntasell i Castellví, Aura, 1972-; Martínez-García, Maria; Tusquets Trias de Bes, Ignacio; Rovira Guerín, Ana; Albanell Mestres, Joan (American Association for Cancer Research (AACR), 2017)
    Purpose: Trastuzumab-emtansine (T-DM1) is a standard treatment in advanced HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify mechanisms of acquired T-DM1 resistance.Experimental Design: ...
  • Martínez Bosch, Neus; Alameda Quitllet, Francisco; Arumí Uría, Montserrat; Bellosillo Paricio, Beatriz; Menéndez, Silvia; Esteve-Codina, Anna; Martínez-García, Maria; Navarro Medrano, Pilar (MDPI, 2023)
    Glioblastoma (GBM) is the most frequent primary malignant brain tumor and has a dismal prognosis. Unfortunately, despite the recent revolution of immune checkpoint inhibitors in many solid tumors, these have not shown a ...
  • Muntasell i Castellví, Aura, 1972-; Cabo, Mariona, 1991-; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Martínez-García, Maria; Rovira Guerín, Ana; Rojo, Federico; Albanell Mestres, Joan; López-Botet, Miguel (Frontiers, 2017)
    Overexpression of the human epidermal growth factor receptor 2 (HER2) defines a subgroup of breast tumors with aggressive behavior. The addition of HER2-targeted antibodies (i.e., trastuzumab, pertuzumab) to chemotherapy ...
  • Balaña, Carmen; Capellades Font, Jaume; Martínez-García, Maria; Alameda Quitllet, Francisco; GLIOCAT Group (Wiley, 2017)
    We explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression (eP) or ...
  • Curigliano, Giuseppe; Gómez Pardo, Patricia; Meric-Bernstam, F.; Conte, Pierfranco; Lolkema, Martijn P.; Beck, Joseph Thaddeus; Bardia, Aditya; Martínez-García, Maria; Pénault-Llorca, Frédérique; Dhuria, Shyeilla; Tang, Z.; Solovieff, Nadia; Miller, Michelle; Di-Tomaso, Emmanuelle; Hurvitz, Sara A. (Elsevier, 2016)
    OBJECTIVES: Cyclin D-cyclin-dependent kinase (CDK) 4/6-inhibitor of CDK4/6-retinoblastoma (Rb) pathway hyperactivation is associated with hormone receptor-positive (HR+) breast cancer (BC). This study assessed the biological ...
  • Martínez-García, Maria; Velasco, Guillermo; Pineda, Estela; Gil-Gil, Miguel J.; Alameda Quitllet, Francisco; Capellades Font, Jaume; Martín-Soberón, Mari Cruz; López-Valero, Israel; Tovar Ambel, Elena; Foro Arnalot, Palmira; Taus García, Álvaro; Arumí Uría, Montserrat; Hernández-Laín, Aurelio; Sepúlveda-Sánchez, Juan Manuel (MDPI, 2022)
    Background: MET-signaling and midkine (ALK ligand) promote glioma cell maintenance and resistance against anticancer therapies. ALK and c-MET inhibition with crizotinib have a preclinical therapeutic rationale to be tested ...
  • Martínez-García, Maria; Álvarez-Linera, Juan; Carrato, Cristina; Ley, L.; Luque, Raquel; Maldonado, X.; Martínez-Aguillo, M.; Navarro, L.M.; Vaz-Salgado, M.A.; Gil-Gil, Miguel J. (SpringerOpen, 2017)
    Glioblastoma (GB) is the most common brain malignancy and accounts for over 50% of all high-grade gliomas. Radiotherapy (RT) with concomitant and adjuvant temozolomide (TMZ) chemotherapy is the current standard of care for ...
  • Majem, Margarita; García-Martínez, E.; Martínez-García, Maria; Muñoz-Couselo, E.; Rodríguez-Abreu, D.; Alvarez, R.; Arance, Ana; Berrocal, A.; de la Cruz-Merino, L.; López-Martín, J.A. (SpringerOpen, 2020)
    The use of immune checkpoint inhibitors has emerged as an effective treatment option for patients with several tumor types. By increasing the activity of the immune system, they can induce inflammatory side effects, which ...
  • Martínez-García, Maria; Servitja Tormo, Sonia; Vilariño Quintela, Noelia; Arance Fernández, Ana; Berrocal Jaime, Alfonso; Cantos Sánchez de Ibargüen, Blanca; Barco Berrón, Sonia del; García Campelo, Rosario; Gironés i Sarrió, Regina; Sepúlveda-Sánchez, Juan Manuel (Springer, 2022)
    Central nervous system (CNS) dissemination is a severe complication in cancer and a leading cause of cancer-related mortality. Brain metastases (BMs) are the most common types of malignant intracranial tumors and are ...
  • Rodríguez Sanz, Maria, 1984-; Pineda-Moncusí, Marta; Servitja Tormo, Sonia; Garcia Giralt, Natàlia; Martos, Tamara; Tusquets Trias de Bes, Ignacio; Martínez-García, Maria; Rodriguez-Morera, Jaime; Díez Pérez, Adolfo; Albanell Mestres, Joan; Nogués Solan, Francesc Xavier (Elsevier, 2016)
    INTRODUCTION: Patients with breast cancer under aromatase inhibitor (AI) treatment often develop osteoporosis and their average bone loss rate is twice that of natural reduction during menopause, increasing fracture risk. ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking